Valeant CEO claims Allergan investors support a buyout vote

Save

Valeant can't make a deal for Allergan if it doesn't get shareholder support for a special meeting. That's where it hopes to overturn Allergan's board and its poison pill defense. But if you ask Valeant CEO J. Michael Pearson, his company is well on its way toward that goal.